IP Library Granted Patent US 12,005,080
Granted Patent B2
US 12,005,080 · App. 17/040,865 · Granted Jun 11, 2024

Method for promoting proliferation of immune cells

Inventors: Youguo Ling (Shanghai, CN); Hao Guo (Shanghai, CN); Xiaowen He (Shanghai, CN); Haili Ma (Shanghai, CN); Huijiao Li (Shanghai, CN); Huajing Wang (Shanghai, CN); Bi Ying (Shanghai, CN); Huanfeng Yang (Shanghai, CN)
Assignee: Oricell Therapeutics Co., Ltd.
A61K35/17A61P35/00C07K14/705C12N5/0636C12N15/86C12N2740/15043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,005,080
App. No.
17/040,865
Granted
Jun 11, 2024
Kind
B2
Abstract

Disclosed is a method for promoting immune cell proliferation. The method comprises the following step: upregulating the expression of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells.

Claims (9)

1. A genetically modified human immune cell, wherein the genetic modification up-regulates an expression of a low density lipoprotein receptor-associated protein or fragment thereof in the genetically modified immune cell, wherein the low density lipoprotein receptor-associated protein is low density lipoprotein receptor-associated protein 6 or the low density lipoprotein receptor-associated protein 5, wherein the low density lipoprotein receptor-associated protein or fragment thereof comprises an intracellular region of the low density lipoprotein receptor-associated protein, wherein the low density lipoprotein receptor-associated protein or fragment thereof comprises an amino acid sequence as set forth in any one of SEQ ID NO: 22, 24, 26, and 28, or an amino acid sequence having at least 80% homology thereof.

2. The genetically modified immune cell according to claim 1 , which expresses a chimeric antigen receptor (CAR) or a T cell receptor (TCR).

3. The genetically modified immune cell according to claim 1 , wherein the low density lipoprotein receptor-associated protein or fragment thereof is derived from a human.

4. The genetically modified immune cell according to claim 1 , wherein the low density lipoprotein receptor-associated protein 6 or fragment thereof further comprises an transmembrane region of the low density lipoprotein receptor-associated protein 6.

5. The genetically modified immune cell according to claim 1 , wherein the low density lipoprotein receptor-associated protein 5 or fragment thereof further comprises an transmembrane region of the low density lipoprotein receptor-associated protein 5.

6. A genetically modified human immune cell, wherein the genetic modification up-regulates an expression of a low density lipoprotein receptor-associated protein or fragment thereof in the genetically modified immune cell, wherein the low density lipoprotein receptor-associated protein is low density lipoprotein receptor-associated protein 6 or the low density lipoprotein receptor-associated protein 5, wherein the low density lipoprotein receptor-associated protein or fragment thereof comprises an intracellular region of the low density lipoprotein receptor-associated protein, wherein a nucleic acid molecule encoding the low density lipoprotein receptor-associated protein or fragment thereof comprises a nucleic acid sequence as set forth in any one of SEQ ID NO: 21, 23, 25, and 27.

7. A method for preparing the genetically modified immune cell of claim 1 , comprising: up-regulating an expression of the low density lipoprotein receptor-associated protein or fragment thereof in the genetically modified immune cell.

8. The method according to claim 7 , further comprising: introducing into the genetically modified immune cell a vector up-regulating the expression of the low density lipoprotein receptor-associated protein or fragment thereof.

9. The method according to claim 8 , wherein the vector is at least one selected from the group consisting of a retroviral vector, a lentiviral vector, and a transposon plasmid.

Assignments (2)
CHANGE OF NAME Recorded Mar 21, 2024
From: ORIGINCELL THERAPEUTICS CO., LTD.
To: ORICELL THERAPEUTICS CO., LTD.
Reel/Frame 066865/0030 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: LING, YOUGUO; GUO, HAO; MA, HAILI; LI, HUIJIAO; WANG, HUAJING; YING, BI; YANG, HUANFENG; HE, XIAOWEN
To: ORIGINCELL THERAPEUTICS CO., LTD.
Reel/Frame 053862/0516 →
Priority Claims (1)
CN 201810251875.7 · Mar 26, 2018 · national
Continuity (1)
Related Publication 20210106620A1 · Apr 15, 2021